At the Suman Paul laboratory, we are focused on developing new antibodies and cell therapies for cancer treatment. Our team of researchers are dedicated to identifying novel targets, mechanisms for cancer therapy and developing innovative solutions to improve patient outcomes. We work closely with basic science researchers and clinicians to accelerate the translation of our discoveries into clinical practice.

The Fukunaga Lab uses multidisciplinary approaches to understand the cell biology, biogenesis and function of RNA-binding proteins and small silencing RNAs from the atomic to the organismal level. The lab studies (1) biology and molecular functions and mechanisms of uncharacterized RNA-binding proteins, and (2) how small silencing RNAs, including microRNAs (miRNAs), small interfering RNAs (siRNAs) and piwi-interacting RNAs (piRNAs), are produced and function. Mutations in the RNA-binding protein and small RNA genes cause many diseases, including cancers. We use a combination of biochemistry, Drosophila genetics, molecular biology, cell culture, and next-generation sequencing, to answer fundamental biological questions and also potentially lead to therapeutic applications to human diseases.

Epstein-Barr virus and Kaposi's sarcoma herpesvirus are found in association with a variety of cancers. Our laboratory studies are aimed at better defining the role(s) of the virus in the pathogenesis of these diseases and the development of strategies to prevent, diagnose or treat them. We have become particularly interested in the unfolded protein response in activation of latent viral infection. Among the notions that we are exploring is the possibility that activation of virus-encoded enzymes will allow the targeted delivery of radation. In addition, we are investigating a variety of virus-related biomarkers including viral DNA, antibody responses, and cytokine measurements that may be clinically relevant.